Scarica l'app Stockscreener
13.79
0.35%
-0.045
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc.VTYX - Your Wyoming Link
Will Ventyx Biosciences Inc. stock split attract more investorsStock Surge & Stepwise Entry/Exit Trade Alerts - ulpravda.ru
Lilly To Buy Ventyx Biosciences For $1.2 Billion To Expand Oral Inflammation Pipeline - Pulse 2.0
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc.VTYX - PR Newswire
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - PR Newswire
Ventyx Biosciences to be Sold to Eli Lilly for $14 per Share - Intellectia AI
Wilson Sonsini Advises Ventyx Biosciences on $1.2 Billion Acquisition by Eli Lilly - Wilson Sonsini
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition By Investing.com - Investing.com Nigeria
Ventyx’s NLRP3 inhibitors best in class? Lilly offers $1.2B - BioWorld MedTech
Is Ventyx Biosciences Inc. stock a defensive play in 2025Forecast Cut & Weekly Stock Breakout Alerts - ulpravda.ru
FDA Limits Oversight of Fitness Wearables as Eli Lilly Acquires Ventyx Biosciences in $1 Billion Deal - geneonline.com
2 Firms Guide Eli Lilly's $1.2B Ventyx Biosciences Acquisition - Law360
Lilly Snags Ventyx For $1.2 Billion; Who Else Benefits? - Investor's Business Daily
Eli Lilly Scoops Up Ventyx Biosciences in $1.2 Billion Acquisition - NAVLIN DAILY
Lilly’s Ventyx Buyout Will Swell Interest In NLRP3 inhibitors - Citeline News & Insights
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX) - MarketScreener
Eli Lilly Boosts Its Immunology Drug Pipeline With $1.2B Ventyx Bio Acquisition - MedCity News
Lilly buys Ventyx in $1.2bn deal to tackle chronic inflammation - BioXconomy
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences - PharmExec.com
Eli Lilly (LLY) Buys Ventyx Biosciences in $1.2 Billion Deal - TipRanks
Eli Lilly To Acquire Ventyx Biosciences In $1.2 Billion Deal - Asianet Newsable
Ventyx Biosciences (VTYX) Downgraded by Wells Fargo to Equal-Wei - GuruFocus
Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1? - Yahoo Finance
Lilly to acquire Ventyx Biosciences stock for $14 per share - Investing.com
Lilly Agrees to Acquire Ventyx Biosciences - Contract Pharma
Eli Lilly stock pops in premarket on $1.2 billion Ventyx deal — what traders watch next - TechStock²
Lilly acquires inflammatory firm Ventyx Biosciences for $1.2bn deal - European Pharmaceutical Review
Eli Lilly stock to acquire Ventyx for $1.2 billion, Cantor Fitzgerald maintains Overweight rating - Investing.com
Lilly announces acquisition of Ventyx Biosciences for around $1.2bn - PMLiVE
VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders - Bluefield Daily Telegraph
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
Ventyx Biosciences (VTYX) Stock Rally Cools as $1.2B Eli Lilly Takeover Triggers Target Cuts - TipRanks
Eli Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammatory Disease Portfolio - geneonline.com
Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact - BioSpace
Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn - Yahoo Finance
Lilly buys inflammation biotech Ventyx for $1.2B in wake of Parkinson's, CV readouts - Fierce Biotech
Eli Lilly in Advanced Talks to Buy Ventyx for About $1 Billion - GuruFocus
Lilly confirms bid to acquire Ventyx Biosciences - The Pharma Letter
Ventyx Biosciences jumps on report Eli Lilly nears more than $1B deal - MSN
Ventyx Biosciences downgraded to Hold from Buy at Canaccord - TipRanks
Ventyx Biosciences downgraded to Neutral from Buy at UBS - TipRanks
Lilly to acquire Ventyx Biosciences stock for $1.2 billion, Canaccord cuts rating - Investing.com Canada
UBS downgrades Ventyx Biosciences stock to Neutral on Eli Lilly acquisition - Investing.com Canada
Eli Lilly to acquire Ventyx Biosciences stock for $1.2 billion as Clear Street downgrades - Investing.com Nigeria
Lilly Commits $1.2B to Transform Oral Therapy Landscape with Ventyx Acquisition - geneonline.com
Lilly Inks $1.2bn Deal For Ventyx In Broader Pipeline Expansion - Citeline News & Insights
Eli Lilly to buy Ventyx Biosciences for $1.2 billion - wibqam.com
Significant price jump for US biotech company - medwatch.com
Eli Lilly (LLY) to Acquire Ventyx Biosciences in $1.2 Billion De - GuruFocus
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases - The Malaysian Reserve
Ventyx downgraded to Market Perform from Outperform at LifeSci Capital - TipRanks
Eli Lilly to Acquire Drug Developer Ventyx for $1.2 Billion, Expanding in Autoimmune Field - Bitget
Lilly to buy Ventyx Biosciences for $1.2 billion - Indian Pharma Post
Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders - Morningstar
Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion, Expanding Inflammation Portfolio - NAI500
Confirming rumours, Lilly to buy Ventyx in $1.2B deal - FirstWord
Eli Lilly confirms plan to buy Ventyx Biosciences in $1.2 billion deal - MSN
Eli Lilly confirms deal to buy Ventyx Biosciences for $14 a share - MSN
Eli Lilly (LLY) Acquires Ventyx Biosciences for $1.2 Billion - GuruFocus
Ventyx stock jumps on Lilly’s $1.2 billion buyout — and why it’s still trading under $14 - TechStock²
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs - BioPharma Dive
Eli Lilly to buy Ventyx Biosciences for $1.2bn - MLex
Eli Lilly to Acquire Ventyx Biosciences in Cash Deal - TipRanks
1.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):